(702) 683-8946

Monday - Friday 9am to 5pm



Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com




Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com




CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform




Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business




Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.


692 Result: Form 10-K

BWXT Joint Venture Awarded $1.5 Billion Environmental Management Contract

May 27th, 2017

LYNCHBURG, Va. / CRWE PRESS RELEASE / May 26, 2017 - BWX Technologies, Inc. (NYSE:BWXT) announced today that its Four Rivers Nuclear Partnership, LLC joint venture with lead partner CH2M and Fluor Corporation was awarded the Paducah Deactivation and . Read more

Diplomat to Dispense KEVZARA(R) for Treatment of Rheumatoid Arthritis

May 25th, 2017

The nation’s largest independent specialty pharmacy has been selected as a preferred pharmacy for the drug KEVZARA® (sarilumab) for rheumatoid arthritis. FLINT, Mich. / CRWE PRESS RELEASE / May 25, 2017 - Diplomat Pharmacy, Inc. (NYSE: D. Read more

Nature's Sunshine Products Receives Direct Selling License in China

May 16th, 2017

LEHI, Utah / CRWE PRESS RELEASE / May 16, 2017 - Nature’s Sunshine Products (NASDAQ: NATR), “the Company”, a leading natural health and wellness company engaged in the manufacture and direct selling of nutritional and personal . Read more

Uranium Resources Reports First Quarter 2017 Profit and Improved Balance Sheet

May 11th, 2017

CENTENNIAL, Colo. / CRWE PRESS RELEASE / May 11, 2017 – Uranium Resources, Inc. (Nasdaq: URRE; ASX: URI), an energy metals exploration and development company, announced today its results for the first quarter of fiscal year 2017, and also. Read more

Astrotech Subsidiary 1st Detect to Pursue Strategic Alternatives

May 10th, 2017

Austin, TX / CRWE PRESS RELEASE / May 10, 2017 - Astrotech Corporation’s (NASDAQ: ASTC) board of directors and management announce that they have engaged Chardan to advise on strategic alternatives involving Astrotech subsidiary 1st Detect Corp. Read more

CP announces intention to launch new share repurchase program and increases dividend by 12.5 percent

May 10th, 2017

Calgary, AB / CRWE PRESS RELEASE / May 10, 2017 - Canadian Pacific Railway Limited (TSX: CP) (NYSE: CP) today announced that the Toronto Stock Exchange ("TSX") has accepted its notice to implement a normal course issuer bid ("NCIB") to purchase, for . Read more

Flotek Industries, Inc. Announces Agreement To Divest Drilling Technologies Segment

May 02nd, 2017

HOUSTON / CRWE PRESS RELEASE / MAY 2, 2017 - Flotek Industries, Inc. ("Flotek" or the "Company") (NYSE: FTK) has entered into a definitive agreement to divest its Drilling Technologies segment to National Oilwell Varco, L.P. (“NOV”) . Read more

IAC's HomeAdvisor to Combine with Angie's List

May 01st, 2017

* Creates clear industry leader in $400 billion home services marketplace * On a pro forma basis, company generated an estimated $17 billion in transaction value over the last 12 months for more than 200,000 paying service providers across the two. Read more

Uranium Resources to Present at Mines and Money New York Conference

April 27th, 2017

CENTENNIAL, Colo. / CRWE PRESS RELEASE / April 27, 2017 - Uranium Resources, Inc. (Nasdaq: URRE; ASX: URI), an energy metals exploration and development company, announced that President and CEO Christopher M. Jones will provide a business updat. Read more

Sajan Enters into Merger Agreement to be Acquired by AMPLEXOR International

April 26th, 2017

Shareholders to Receive $5.83 in Cash per Share; Transaction Valued at Approximately $28.5 Million RIVER FALLS, Wis. and Bertrange, Luxembourg / CRWE PRESS RELEASE / April 26, 2017 - Sajan Inc. (Nasdaq: SAJA) and AMPLEXOR International SA, today a. Read more

Wells Fargo Announces Preliminary Voting Results of 2017 Annual Meeting

April 25th, 2017

Ponte Vedra Beach, Florida / CRWE PRESS RELEASE / April 25, 2017 - Wells Fargo & Company (NYSE: WFC) announced that based on preliminary voting results at today’s 2017 Annual Meeting of Stockholders all 15 directors were re-elected with a major. Read more

Tyson Foods Explores the Sale of Three Non-Protein Businesses as Part of Corporate Strategy

April 24th, 2017

Company focused on growing portfolio of protein-packed brands Springdale, Ark. / CRWE PRESS RELEASE / April 24, 2017 – As part of its strategic focus on protein-packed brands, Tyson Foods, Inc. (NYSE: TSN) is exploring the sale of three non-. Read more

Cancer Genetics, Inc. Launches a Unique, Industry-Leading Panel That Provides Comprehensive & Precise Information for Immuno-Oncology Therapy Assessment & Patient Monitoring

April 24th, 2017

* Complete::IO™ provides immune endpoint and immune monitoring of patients allowing informed therapeutic decisions and assessment of potential toxicities of IO therapies in blood cancers and solid tumors * Complete::IO™ can determine pre. Read more

Diplomat Will Dispense ZEJULA(TM) to Treat Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

April 19th, 2017

The nation’s largest independent specialty pharmacy has been selected to the specialty pharmacy panel to dispense ZEJULA™ (niraparib). FLINT, Mich. / CRWE PRESS RELEASE / April 19, 2017 – Diplomat Pharmacy, Inc. (NYSE: DPLO), ha. Read more

Nivalis Therapeutics and Alpine Immune Sciences Agree to Combine

April 18th, 2017

- Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology - - Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development - - Existing Investors OrbiMed Advisors. Read more

Load More Content